14 citations
,
January 2018 in “Skin Appendage Disorders” Upper eyelid hyperpigmentation can help diagnose facial lichen planus pigmentosus in patients with frontal fibrosing alopecia.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” PP405 may help hair growth by activating hair follicle stem cells.
25 citations
,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
8 citations
,
August 2021 in “Lupus Science & Medicine” Patients with cutaneous lupus are most concerned about self-consciousness, physical symptoms, and disease progression.
41 citations
,
December 2017 in “Lasers in Medical Science” Low-Level Laser Therapy (LLLT) is a safe and effective treatment for common hair loss, but more research is needed to find the best power and wavelength for treatment.
September 2023 in “Journal of the American Academy of Dermatology” The cleanser gel significantly reduces facial oiliness.
May 2025 in “Reactions Weekly”
7 citations
,
September 2006 in “Clinical lymphoma & myeloma” Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.
35 citations
,
August 1978 in “Australian Veterinary Journal” Feeding steers only Leucaena leucocephala causes severe health issues and poor weight gain.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
6 citations
,
January 2016 in “Journal of lasers in medical sciences” One session of Low Level Laser Therapy before hair transplantation doesn't significantly improve hair growth.
July 2005 in “Hair transplant forum international” September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
December 2023 in “Natural product research” Lignans from Urtica triangularis may help treat benign prostatic hyperplasia (BPH).
January 2024 in “Journal of cosmetic dermatology” Silibinin-loaded micelles significantly protect hair from UV-B damage.
65 citations
,
November 2008 in “Pediatric Dermatology” Phototherapy is effective and well-tolerated for treating childhood psoriasis and pityriasis lichenoides chronica.
Combining PRP with low-level laser therapy is better for hair growth than PRP alone.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
Biotin can help improve hair condition and reduce hair loss.
16 citations
,
December 2001 in “The Journal of Dermatology” A woman recovered from hair loss and skin eruptions after stopping a tuberculosis drug and using steroids.
May 2023 in “Zenodo (CERN European Organization for Nuclear Research)”
February 2024 in “Future science OA” Loss of the Y chromosome and UTY gene activity increases cancer risk in men.
3 citations
,
October 2020 in “UNC Libraries” The new criteria for classifying lupus are more accurate and comprehensive.
January 2021 in “American Academy of PediatricsItasca, IL eBooks” Telogen effluvium is a condition that causes temporary hair loss due to stress or shock to the body.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
December 2017 in “PubMed” Low-level laser therapy may help treat hair loss with fewer side effects.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.